rs12144344 — ST6GALNAC3

Intronic variant in sialyltransferase ST6GALNAC3 associated with higher circulating vitamin D-binding protein levels through altered glycosylation of DBP

See your personal result for ST6GALNAC3

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

ST6GALNAC3 — Glycosylation Shapes How Much Vitamin D Your Body Carries

Vitamin D does not travel through the bloodstream on its own. Around 85–90% of circulating vitamin D is bound to a carrier protein called vitamin D-binding protein11 vitamin D-binding protein
VDBP, also known as GC-globulin, is a glycoprotein encoded by the GC gene on chromosome 4. It carries most of the 25(OH)D and 1,25(OH)2D in the blood and determines how long vitamin D stays in circulation. (VDBP). The rs12144344 variant in the ST6GALNAC3 gene represents an emerging link between the biology of protein glycosylation and vitamin D status — a pathway that influences how VDBP is processed and how much of it circulates in your blood.

The Mechanism

ST6GALNAC3 encodes a sialyltransferase22 sialyltransferase
An enzyme that attaches sialic acid residues to the ends of sugar chains on glycoproteins and glycolipids, modifying their structure, stability, and biological activity enzyme that adds sialic acid residues to O-linked glycan chains on glycoproteins. VDBP itself is a glycoprotein: the Gc1 isoforms (the most common forms) carry an O-linked trisaccharide at threonine 418 that includes a terminal sialic acid residue. The terminal sialic acid is added by a sialyltransferase, and ST6GalNAc family enzymes are strong candidates for this modification. Variants in ST6GALNAC3 may alter the enzyme's activity, changing the sialylation state of VDBP. Different sialylation patterns affect VDBP's isoelectric properties, half-life in circulation, and possibly its overall concentration. The rs12144344 variant lies in an intron and most likely influences gene expression or splicing rather than the enzyme's active site directly.

The Evidence

In a genome-wide association study of 1,380 Finnish men33 genome-wide association study of 1,380 Finnish men
Moy KA et al. Genome-wide association study of circulating vitamin D-binding protein. Am J Clin Nutr, 2014 from the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) cohort, rs12144344 was the third strongest genetic signal for circulating VDBP levels. Each copy of the T allele was associated with an increase of approximately 396 nmol/L in serum VDBP (SE = 80.21, P = 5.9 × 10⁻⁷). Across genotype groups, mean VDBP concentrations were 5,408 nmol/L (CC), 5,825 nmol/L (CT), and 6,200 nmol/L (TT) — a roughly 15% step-wise increase per allele. This was the first genome-wide scan for VDBP as a distinct biochemical endpoint and the first study to implicate ST6GALNAC3 in vitamin D biology.

The association was genome-wide suggestive (P < 5 × 10⁻⁶) in the European cohort but was not replicated in an African-ancestry GWAS of VDBP44 African-ancestry GWAS of VDBP
Wang et al. 2023 — GWAS of circulating vitamin D outcomes among individuals of African ancestry, n = 9,536. PMC10196601 (β = −0.06, SE = 0.04, P = 0.17), suggesting the effect may be population-specific or that the original signal was driven by European-ancestry linkage disequilibrium. The variant has not been assessed in large vitamin D GWAS as a direct endpoint.

Because this variant affects VDBP concentration (total carrier protein) rather than the vitamin D activation or receptor pathway, it operates differently from the major GC variants (rs7041, rs4588). Higher VDBP means more protein-bound vitamin D in circulation but does not necessarily mean more biologically active (free) vitamin D at the cellular level.

Practical Implications

TT homozygotes in the European cohort had VDBP concentrations approximately 15% above CC homozygotes. Higher VDBP generally means higher total 25(OH)D on standard blood tests, but free (biologically active) vitamin D may not increase proportionally — more carrier protein can sequester more vitamin D without increasing delivery to tissues. This raises the possibility that TT carriers with seemingly adequate total 25(OH)D may have less freely available vitamin D at the cellular level.

The effect size is modest compared to the primary GC variants (rs7041 and rs4588 each account for much larger differences in VDBP), and the lack of replication in non-European populations means this variant should be interpreted cautiously. Where available, testing free 25(OH)D alongside total provides a more complete picture of functional vitamin D status.

Interactions

The primary determinants of serum VDBP and vitamin D transport are rs7041 and rs4588 in the GC gene itself. rs12144344 appears to modulate VDBP levels through a separate glycosylation pathway, making it biologically additive to (rather than redundant with) the GC variants. If an individual carries both higher-VDBP GC alleles and the rs12144344-T allele, the combined effect on total VDBP concentration — and the gap between total and free vitamin D — could be greater than either variant alone. This interaction has not been formally studied.

Nutrient Interactions

vitamin D altered_metabolism

Genotype Interpretations

What each possible genotype means for this variant.

CC Normal

Standard ST6GALNAC3 function — typical vitamin D-binding protein levels

You carry two copies of the reference C allele at rs12144344. In the genome-wide association study that identified this variant, CC homozygotes had mean serum VDBP concentrations of approximately 5,408 nmol/L — the lowest of the three genotype groups, corresponding to typical population levels. About 39% of people globally share this genotype, rising to roughly 34% in Europeans.

Your ST6GALNAC3 genotype does not appear to meaningfully alter your vitamin D-binding protein levels above baseline.

CT Intermediate

One T allele — modestly elevated vitamin D-binding protein levels

You carry one copy of the T allele at rs12144344. In a genome-wide association study of circulating VDBP in 1,380 Finnish men, each T allele was associated with approximately 396 nmol/L higher serum VDBP (P = 5.9 × 10⁻⁷). CT heterozygotes had mean VDBP of about 5,825 nmol/L — midway between CC (5,408) and TT (6,200). This is the most common genotype globally at about 47% of the general population.

Higher VDBP means more vitamin D is protein-bound in your circulation. Standard blood tests measure total 25(OH)D, which may read slightly higher than average without a corresponding increase in free, biologically active vitamin D.

TT High

Two T alleles — elevated vitamin D-binding protein levels; higher total but potentially lower free vitamin D

The TT genotype at rs12144344 confers the largest VDBP-raising effect identified for this variant. The GWAS by Moy et al. (2014) studied 1,380 Finnish men from the ATBC cohort and found a genome-wide suggestive association (P = 5.9 × 10⁻⁷). The proposed mechanism is that ST6GALNAC3 sialylation modifies VDBP's glycan structure, altering its hepatic clearance rate or circulating half-life. Slower VDBP clearance would result in higher steady-state concentrations.

Clinically, the distinction between total and free vitamin D is important. VDBP binds 25(OH)D with high affinity; only the ~0.03% of unbound vitamin D can diffuse into cells without active transport. The TT genotype's elevated VDBP is analogous to a larger storage depot: more total vitamin D in circulation, but potentially less available at the cellular level per unit of total 25(OH)D. This is a subtler effect than the primary GC variants (rs7041, rs4588), which directly alter the VDBP protein structure and have much larger effect sizes.

The lack of replication in African ancestry (Wang et al. 2023) may reflect different linkage disequilibrium structure around rs12144344 in that population, or may indicate the original signal was a false positive at genome-wide suggestive (not genome-wide significant) threshold.